Introduction
The International Association for the Study of Pain (IASP) defines pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. The sensation of pain involves multiple signaling pathways, numerous neurotransmitters, and other mediators that are involved in the inhibitory or facilitatory control of pain intensity. These mechanisms affect the perception of stimuli as non-painful or painful, respectively, but their positive or negative modulation of pain signaling is strongly dependent on the receptor type involved and its location in the target tissue (Argoff
2011).
In living organisms, endogenous opioids (endorphins, enkephalins, and dynorphins) are key molecules in the descending pain suppression pathways. Recently, it has been discovered that opioid receptors are widely distributed not only in the central but also peripheral nervous system and in the non-neuronal tissues. There is also evidence from animal and human studies for the involvement of peripheral opioid receptors in analgesia, especially in the presence of inflammation (Sehgal et al.
2011), or neuropathy (Plein and Rittner
2017).
The nociceptin/orphanin FQ opioid peptide receptor (NOP receptor) is the most recently discovered member of the opioid receptor family. Together with its endogenous ligand–nociceptin, also known as orphanin FQ (N/OFQ), it forms the fourth member of the opioid receptor family which is abundantly expressed in various body tissues. A large body of evidence shows that the activation of N/OFQ-NOP system regulates functions of the central nervous system being implicated in feeding, body weight homeostasis, stress, stress-related psychiatric disorders—depression, anxiety, drug, and alcohol dependence (Witkin et al.
2014). Data from preclinical studies are also in line with these findings showing that N/OFQ plays an important role in comorbid neuropathic pain and post-traumatic stress disorder (Zhang et al.
2015), acute and chronic restraint stress responses (Delaney et al.
2012), depression (Vitale et al.
2017), and other stress-related conditions (Leggett et al.
2006; Witkin et al.
2014).
Apart from this, the N/OFQ-NOP pathway is also involved in the modulation of inflammatory and immune responses of the body by influencing migration of leucocytes, cytokine secretion, and lymphocyte proliferation. Recent findings showing the involvement of N/OFQ in inflammatory responses (Gavioli and Romão
2011) and the evidence for a role of NOP receptors and N/OFQ in the modulation of neurogenic inflammation, migraine (Tajti et al.
2015), and airway tone (Singh et al.
2016) led to the hypothesis that N/OFQ-NOP system might be an important drug target for analgesic drugs. This is in part supported by the previous findings showing that the blockade of NOP receptors can attenuate inflammation (Gavioli et al.
2015). On the other hand, this issue is not completely clear and unequivocally explored as there is also evidence for analgesic efficacy of NOP agonists in neuropathic and inflammatory pain, both in animal models (Sukhtankar et al.
2013) and clinical trials (Sałat et al.
2015a).
Cebranopadol (a.k.a. GRT-6005; trans-6′-fluoro-4′,9′-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1′(3′H)-pyrano[3,4-b]indol]-4-amine) is a dually acting nociceptin/orphanin FQ and opioid receptor agonist (K
i (nM)/EC
50 (nM)/relative efficacy (%): human NOP receptor 0.9/13.0/89; human mu-opioid peptide (MOP) receptor 0.7/1.2/104; human kappa-opioid peptide (KOP) receptor 2.6/17/67; human delta-opioid peptide (DOP) receptor 18/110/105) (Linz et al.
2014) that has been recently developed in Phase 2 clinical trials for painful diabetic neuropathy or cancer pain (reviewed in Sałat et al.
2015a). It showed analgesic properties in various rat models of acute thermal pain, i.e., tail-flick model, chronic inflammatory pain (CFA-induced arthritis model), bone cancer pain model (Raffa et al.
2017), and neuropathic pain: chronic constriction injury (CCI) and diabetic neuropathic pain models (Raffa et al.
2017) after intraplantar, intracerebroventricular, intrathecal, intravenous (Tzschentke et al.
2017), subcutaneous, or oral route (Linz et al.
2014). Compared to selective MOP receptor agonists, cebranopadol was more potent in models of chronic neuropathic than acute nociceptive pain and its duration of action was long (Linz et al.
2014). Noteworthy, safety pharmacology studies with cebranopadol demonstrated that the development of analgesic tolerance in cebranopadol-treated animals subjected to CCI procedure was delayed as compared to equi-analgesic doses of morphine (Sałat et al.
2015a), and at analgesic doses, cebranopadol did not cause respiratory depression in a rat whole-body plethysmography model, or motor coordination deficits in the rat rotarod test (Linz et al.
2014,
2017; Lambert et al.
2015; Günther et al.
2017).
The data presented above come from rat studies and there is limited knowledge about antinociceptive properties of cebranopadol in mice. Moreover, these previous studies investigated the influence of cebranopadol on tactile allodynia but not thermal (i.e., heat or cold) allodynia and hyperalgesia. Hence, in the present study, we utilized mouse models of acute, tonic, and chronic pain induced by thermal or chemical (inflammatory) stimuli, with a particular emphasis on pharmacoresistant chronic neuropathic pain evoked by oxaliplatin. Oxaliplatin is a third-generation platinum-based anti-tumor drug used to treat advanced colorectal cancer. Compared to other platinum-based drugs, it has lower incidence of hematological adverse effects and gastrointestinal toxicity, but in approximately 95% of patients, oxaliplatin causes severe neuropathic pain episodes and increased sensitivity to cold (Manji
2013) which often lead to dose reduction or even treatment discontinuation. These neuropathic pain episodes can be effectively attenuated by μ opioid peptide (MOP) and NOP receptor agonists (Micheli et al.
2015).
In the present study, we investigated the effect of cebranopadol on cold nociceptive threshold of oxaliplatin-treated mice. We used two protocols of its administration: the first one which utilized this drug alone, and the second one in which cebranopadol was used in combination with simvastatin. Available data show potential effectiveness of simvastatin in several animal models of pain (Shi et al.
2011; Miranda et al.
2011; Chen et al.
2013; Mansouri et al.
2017), including inflammatory (Chen et al.
2013) and neuropathic pain models (Shi et al.
2011). First, in the previous studies (Bhalla et al.
2015), simvastatin effectively reversed vincristine-induced neuropathic pain by anti-inflammatory effects and it was able to attenuate vincristine-induced increase in myeloperoxidase activity. Second, anti-inflammatory and anti-oxidant effects of this drug also resulted in reduction of cisplatin-induced nephrotoxicity and hepatotoxicity in rats (Işeri et al.
2007) and simvastatin protected Sertoli cells against cisplatin cytotoxicity (Wang et al.
2015). Third, it has been also shown that simvastatin was able to attenuate neuropathic pain induced by CCI in rats and it significantly decreased the ratio of membrane/cytosolic RhoA by reducing RhoA/LIMK/cofilin pathway activity (Qiu et al.
2016). Furthermore, it exerted antihyperalgesic and antiallodynic effects through the inhibition of spinal RhoA activation and its daily intrathecal administration before nerve injury prevented the development of neuropathy in nerve-ligated mice (Ohsawa et al.
2016). Interestingly, the RhoA-dependent pathway is implicated in the regulation of Transient receptor potential melastatin subtype 8 (TRPM8), a cold-sensing cation channel (Sun et al.
2014) which is also required for cold-related symptoms of oxaliplatin-induced peripheral neurotoxicity (Knowlton et al.
2011; Kono et al.
2012). Taken together, these data clearly suggest that statins are effective in neuropathic pain conditions and they might modulate pain sensitivity of cold-exposed subjects. This justifies the rationale to undertake this part of research which aimed to assess if combined use of simvastatin and cebranopadol could attenuate cold hypersensitivity of oxaliplatin-treated mice.
Discussion
In this study, we implemented mouse models of acute, tonic, and chronic pain to assess antinociceptive properties of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist. Antinociceptive efficacy of cebranopadol was compared to that of morphine used at an equal dose. A summary of results obtained for both drugs in various mouse pain tests is presented in Table
1.
Table 1
Comparison of antinociceptive properties of cebranopadol and morphine in mouse models of pain
Hot plate test (acute thermal pain) | CEB = MORa
| |
Writhing test (acute inflammatory pain) | CEB = MOR | |
Capsaicin test (acute neurogenic pain) | CEB = MOR | |
Formalin test (tonic—neurogenic and inflammatory pain) | CEB < MOR | |
Cold plate test (oxaliplatin-induced neuropathic pain) | CEB ≥ MOR | |
In the hot plate test, both cebranopadol and morphine demonstrated strong and statistically significant antinociceptive properties. Of note, the activity of cebranopadol was delayed as compared to that previously shown for morphine (90–120 min vs. 30–60 min for cebranopadol and morphine, respectively) (Gades et al.
2000; Sałat et al.
2012). The hot plate assay is a rodent model of acute pain. The paws of mice are very sensitive to heat at temperatures that are not harmful to the skin. The characteristic responses such as jumping, licking of the paws are of central origin and it is thought that drugs with antinociceptive properties in the hot plate test act primarily in the spinal medulla and/or higher central nervous system levels (Vogel and Vogel
1997). In this assay, peripherally acting analgesics are generally not active (Vogel and Vogel
1997). Thus, the results obtained in the present study confirmed the role of central opioidergic system in mediating analgesia caused by cebranopadol (and morphine).
Available literature data indicate that functional NOP and MOP receptors are expressed not only at spinal and supraspinal sites of the ascending and descending pain pathways but also in the periphery. NOP receptors and their ligand—N/OFQ have been found in many peripheral organs (e.g., airways and cardiovascular system) and in the immune system in rodents and humans (Schröder et al.
2014). In a rat model of inflammatory pain (i.e., trinitrobenzene sulfonic acid (TNBS)-induced colonic hyperalgesia), N/OFQ demonstrated antihypersensitive effects after peripheral administration and it was antinociceptive in the capsaicin test in mice (Sakurada et al.
2005). N/OFQ exerted analgesic properties in the tail-flick test in rats (Xu et al.
1996; Tian et al.
1997) and mice (King et al.
1997). Moreover, spinal N/OFQ potentiated analgesia caused by systemic morphine (Tian et al.
1997), while a selective non-peptide NOP receptor agonist, SCH-221510, showed anti-inflammatory and analgesic properties in a mouse model of TNBS-induced inflammatory bowel disease after systemic administration (Sobczak et al.
2013,
2014).
In line with these findings, in our present study, both cebranopadol and morphine attenuated chemogenic, inflammatory acute pain responses induced by acetic acid. Since the writhing test is regarded a rodent model of pain mediated by peripheral mechanisms related to inflammation (Vogel and Vogel
1997), it seems plausible that peripheral NOP and MOP receptors might play a role in the observed activity of both drugs. The involvement of NOP receptors in the pathophysiology of inflammation, arterial hypertension, and cardiac or brain circulatory ischemia has been reported previously (reviewed in Schröder et al.
2014). In the rat model of carrageenan-induced inflammation, i.t. N/OFQ inhibited thermal hyperalgesia (Yamamoto et al.
1997b; Hao et al.
1998), and NOP receptors and their endogenous ligand—N/OFQ modulated neurogenic inflammation and other functions, such as airway tone and caliber (Singh et al.
2016).
The influence of cebranopadol and morphine on peripherally expressed opioid receptors might also explain their activity observed in the capsaicin test. This pain test reflects acute inflammatory pain responses related to neurogenic inflammation. Capsaicin is an exogenous activator of the TRPV1 channels present in sensory neurons, mainly in C-fibers and, to a lesser extent, Aδ. It shows a biphasic effect, i.e., it stimulates TRPV1 located in sensory neurons, resulting in a rapid phase of neurogenic pain with a burning sensation, local vascular and extravascular responses, after which persistent desensitization with concomitant long lasting analgesia appears (reviewed in Sałat et al.
2013b; Marwaha et al.
2016). Previously, it was shown that NOP receptor activation abolished capsaicin-induced contraction of guinea pig airways (Shah et al.
1998; Corboz et al.
2000), reduced capsaicin-induced bronchoconstriction, and increased airway hyper-responsiveness in ovalbumin-sensitized mice (D’Agostino et al.
2010). Of note, in the peripheral nervous system, N/OFQ inhibited neurotransmitter release (Giuliani et al.
2000) and inhibited substance P-mediated nociception in mice (Inoue et al.
1999). Considering an important role of substance P in neurogenic inflammation caused by capsaicin, the antinociceptive activity of cebranopadol in the capsaicin test can be explained in terms of its influence on neurogenic inflammation.
In the formalin test—a tonic pain model, cebranopadol was slightly less active than morphine. This was observed both in the acute (neurogenic) phase, and in the late (inflammatory) phase of this test. Intraplantar formalin induces chemogenic pain that results from neurogenic inflammation, sensory C-fibers activation, as well as sensitization within the spinal cord dorsal horn and the brain (Hunskaar and Hole
1987; Tjølsen et al.
1992; Yashpal and Coderre
1998), but there is also evidence that formalin is a potent stimulator of TRPA1 channels (McNamara et al.
2007; Nassini et al.
2015; Sałat and Filipek
2015). Our present study shows that NOP/MOP receptor activation might also mediate analgesia in the formalin test. It was previously demonstrated that in the formalin test, N/OFQ was antinociceptive after intrathecal administration, whereas it exerted pronociceptive effects and antagonized opioid analgesia when administered intracerebroventricularly (Erb et al.
1997; Yamamoto et al.
1997a; Zhu et al.
1997; Hao and Ogawa
1998; Wang et al.
1999). This bidirectional and site-specific modulation of nociception was also confirmed in the mouse formalin test in which UFP-101, a peptide antagonist selective for NOP receptors, exerted antinociceptive and pronociceptive effects after intracerebroventricular and intrathecal administration, respectively (Rizzi et al.
2006). Antihyperalgesic activity in the formalin test was also observed after systemic administration of selective, non-peptide NOP receptor agonist GRT-TA2210 (Linz et al.
2013).
In animals treated with oxaliplatin, the pain threshold for cold nociception is significantly lower as compared to non-treated mice. This was confirmed in our study in the cold plate test and indicated for the development of cold allodynia in oxaliplatin-treated mice. Recently, it has been shown that tactile allodynia and cold allodynia in rodents treated with oxaliplatin are mediated by TRPA1 stimulation (Nassini et al.
2011; Zhao et al.
2012; Sałat et al.
2013b; Marwaha et al.
2016) and a single dose of oxaliplatin induces acute cold hypersensitivity associated with an enhanced responsiveness of TRPA1 channels (Zhao et al.
2012). The antiallodynic activity of cebranopadol (and morphine) in the oxaliplatin model of neuropathic pain, in particular in the acute phase, together with the results obtained in the formalin test indicate that both drugs tested are able to attenuate TRPA1-mediated pain responses in mice. To the best of our knowledge, this drug has not been evaluated in these pathological conditions previously and our present study confirmed its potential utility for patients suffering from oxaliplatin-induced neuropathic pain. This is a potentially interesting finding as classical opioid drugs have limited efficacy in neuropathic pain conditions and they are regarded the third-line (morphine) or the second-line (tramadol) treatment for neuropathic pain (Finnerup et al.
2015), which is in part due to a diversity of mechanisms underlying the development of neuropathic pain (Torrance et al.
2013).
The expression of NOP receptors is up-regulated in chronic (neuropathic and inflammatory) pain conditions (Briscini et al.
2002; Chen and Sommer
2006; Schröder et al.
2014) and N/OFQ showed antihypersensitive effects in various rodent models of neuropathic pain, including rat CCI model (Yamamoto et al.
1997b; Corradini et al.
2001; Courteix et al.
2004), spinal nerve ligation (SNL) model (Ju et al.
2013), as well as the mouse diabetic neuropathic pain model (Kamei et al.
1999). In addition, some non-peptide NOP receptor agonists (SR14150 and SR16835) displayed NOP receptor-dependent antiallodynic activity in SNL model in mice (Khroyan et al.
2011), whereas in the mouse CCI model, GRT-TA2210 and Ro65-6570 demonstrated strong antiallodynic effects after spinal, supraspinal, and systemic administration (Linz et al.
2013).
Strong anti-inflammatory activity of cebranopadol, as well as the previously reported role of MOP, NOP receptors and N/OFQ in the attenuation of inflammation led us to investigate, if cebranopadol might potentiate/modulate the antiallodynic activity of other drugs with anti-inflammatory properties in chronic pain conditions. For this purpose, we chose the oxaliplatin neuropathic pain model and we used simvastatin as a potential novel treatment option for this pharmacoresistant pain type. Among numerous pathomechanism inflammation has been discovered as one of the key factors underlying neurotoxicity of oxaliplatin (Massicot et al.
2013; Waseem and Parvez
2016). Anti-inflammatory and analgesic properties of simvastatin in neuropathic pain conditions have been widely described in the literature (Miranda et al.
2011; Jaiswal and Sontakke
2012). Moreover, it has been shown that statins have protective effect on ultrastructural alterations induced by cold stress in rats (Bombig et al.
2003). They are also able to attenuate mitochondrial injury induced by cold exposure, inhibit the elevation of blood pressure in cold-treated mice via the downregulation of Bcl-2 pathway (Liang et al.
2017), and they are effective in the attenuation of Raynaud’s phenomenon (Baumhäkel and Böhm
2010). This activity of simvastatin is complex and it involves various pleiotropic effects, such as modulation of endothelial functions and Rho-kinase inhibition, which, in turn, affects TRPM8 activity (Sun et al.
2014). Taken together, these data clearly suggest that statins might modulate body functioning of cold-exposed subjects.
In the cold plate test in oxaliplatin-treated mice compared to non-treated controls, a significant reduction of latency time to pain reaction was observed both 3 h and 7 days after its administration. This indicated the development of cold allodynia in oxaliplatin-treated mice. Cold allodynia in neuropathic mice was not influenced by a single dose of simvastatin administered alone (see results for the early phase), but in contrast to this, a 7-day treatment with this drug partially reversed allodynia induced by cold and the difference between latencies of non-neuropathic mice and oxaliplatin + repeated simvastatin-treated mice was no longer significant. Thus, it might indicate that the repeated administration of simvastatin elevated pain threshold of animals with CIPN. The addition of cebranopadol to simvastatin did not demonstrate additional benefits. Of note, a simultaneous treatment with both drugs reduced latency time to pain reaction. Numerous studies have shown that the hot/cold plate test latencies might decrease with a repeated testing and this decrease may involve learning abilities, differences in animals’ weight, habituation time, and other unknown factors (Czopek et al.
2016). Of note, cebranopadol added to oxaliplatin + repeated simvastatin-treated mice 4 h or 6 h after the last dose of simvastatin (day 7) did not reduce the latency time to pain reaction and a tendency towards the prolongation of this parameter was noted. This is an interesting finding which requires further studies, but it may potentially suggest some pharmacodynamic interaction at the common site of action.
The rotarod test was involved for a proper interpretation of data obtained in pain tests to avoid the possibility of false positive results (Vogel and Vogel
1997). The results of our study showed no motor deficits in mice treated with cebranopadol and this finding is in line with the previous literature data (Bird and Lambert
2015).
To conclude, in this study using mouse models of acute, tonic, and chronic pain, we demonstrated antinociceptive and antiallodynic properties of cebranopadol—a novel, first-in-class agonist at nociceptin/orphanin FQ and opioid receptors. Of note, the antiallodynic activity of cebranopadol in neuropathic pain related to CIPN was shown for the first time, indicating a potential novel treatment option for this type of chronic pain. Apart from this, the results from our present study suggest that NOP receptors might be an important drug target for analgesics used not only in neuropathic pain conditions but also in inflammatory pain. This is of particular relevance in terms of pharmacoresistance of these types of chronic pain to currently available analgesic drugs.